Risk-Benefit_Manuscript_revised_supporting_material_20171025a_w_tables2.pdf (1.19 MB)
Supplemental Material, Risk-Benefit_Manuscript_revised_supporting_material_20171025a_w_tables2 - Analysis of the Risks and Benefits of New Chemical Entities Approved by the US Food and Drug Administration (FDA) and Subsequently Withdrawn From the US Market
journal contribution
posted on 2018-01-10, 12:00 authored by Peter A. Patriarca, R. Michael Van Auken, Scott A. KebschullSupplemental Material, Risk-Benefit_Manuscript_revised_supporting_material_20171025a_w_tables2 for Analysis of the Risks and Benefits of New Chemical Entities Approved by the US Food and Drug Administration (FDA) and Subsequently Withdrawn From the US Market by Peter A. Patriarca, R. Michael Van Auken, and Scott A. Kebschull in Therapeutic Innovation & Regulatory Science